دورية أكاديمية
أعرض في EDS

An Magnetic Resonance Imaging-directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: "Less Is More".

التفاصيل البيبلوغرافية
العنوان: An Magnetic Resonance Imaging-directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: "Less Is More".
المؤلفون: Hagens MJ; Department of Urology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands.; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands., Noordzij MA; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands.; Department of Urology, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands., Mazel JW; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands.; Department of Urology, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands., Jager A; Department of Urology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands., Boellaard TN; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands., Tielbeek JAW; Department of Radiology, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands., Henebiens M; Department of Radiology, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands., Schoots IG; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands., van Leeuwen PJ; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands.; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands., van der Poel HG; Department of Urology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, The Netherlands.; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands., Rynja SP; Prostate Cancer Network Netherlands, Amsterdam, The Netherlands.; Department of Urology, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands.
المصدر: European urology open science [Eur Urol Open Sci] 2022 Aug 02; Vol. 43, pp. 68-73. Date of Electronic Publication: 2022 Aug 02 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101771568 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-1683 (Electronic) Linking ISSN: 26661683 NLM ISO Abbreviation: Eur Urol Open Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2020]-
مستخلص: Background: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa).
Objective: To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach.
Design Setting and Participants: This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2-5 cancers were considered csPCa.
Outcome Measurements and Statistical Analysis: The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores.
Results and Limitations: A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0-99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6-21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9-5.6, p  < 0.001).
Conclusions: An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI.
Patient Summary: Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach.
(© 2022 The Authors.)
References: Urology. 2017 Apr;102:178-182. (PMID: 27871829)
Lancet. 2017 Feb 25;389(10071):815-822. (PMID: 28110982)
Eur Radiol. 2012 Apr;22(4):746-57. (PMID: 22322308)
BJU Int. 2014 Dec;114(6b):E105-E112. (PMID: 24673731)
Eur Urol. 2016 Nov;70(5):846-853. (PMID: 26810346)
Eur Urol. 2019 Sep;76(3):340-351. (PMID: 30898406)
Eur Urol Focus. 2021 Nov;7(6):1300-1307. (PMID: 32660838)
Eur Urol. 2013 Dec;64(6):876-92. (PMID: 23787356)
Eur Urol. 2020 Jan;77(1):78-94. (PMID: 31326219)
Eur Radiol. 2020 Oct;30(10):5404-5416. (PMID: 32424596)
Radiology. 2010 Oct;257(1):14-7. (PMID: 20851935)
Eur Urol. 2019 Apr;75(4):570-578. (PMID: 30477981)
Urol Oncol. 2019 Jan;37(1):57-62. (PMID: 30446460)
Am J Surg Pathol. 2020 Aug;44(8):e87-e99. (PMID: 32459716)
Eur J Radiol. 2021 Apr;137:109587. (PMID: 33592552)
J Urol. 2021 Mar;205(3):740-747. (PMID: 33026927)
Eur Urol Open Sci. 2022 May 02;40:95-103. (PMID: 35540708)
Lancet Oncol. 2019 Jan;20(1):100-109. (PMID: 30470502)
N Engl J Med. 2016 Oct 13;375(15):1415-1424. (PMID: 27626136)
Eur Urol Oncol. 2020 Oct;3(5):615-619. (PMID: 32646850)
BJU Int. 2020 Feb;125(2):260-269. (PMID: 31306539)
Eur Urol. 2022 Sep;82(3):303-310. (PMID: 35115177)
BJU Int. 2020 Jul;126(1):97-103. (PMID: 32124525)
BMC Urol. 2016 Nov 17;16(1):68. (PMID: 27855661)
Eur Urol. 2016 Aug;70(2):332-40. (PMID: 26995327)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
Eur Urol. 2021 Feb;79(2):243-262. (PMID: 33172724)
فهرسة مساهمة: Keywords: Cognitive fusion; Perilesional systematic biopsies; Prostate biopsies; Transperineal
تواريخ الأحداث: Date Created: 20221110 Latest Revision: 20221111
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9638771
DOI: 10.1016/j.euros.2022.07.006
PMID: 36353069
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-1683
DOI:10.1016/j.euros.2022.07.006